Search clinical trials for: BI 113608 PIB bid

Total 124 results

Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 113608 in Healthy Male Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim

Completed

Study to Investigate the Relative Bioavailability, Influence of Pantoprazole Coadministration and Food Effect of Different Oral Formulation of BI 113608

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BI 113608 in Healthy Asian and Caucasian Male Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

First in Man Trial of BI 113608

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 in Otherwise Healthy Controlled Asthmatic Subjects

Healthy | Asthma

Germany
Boehringer Ingelheim

Completed

Bioavailability of Soft Gelatin Capsule Formulation of BI 201335 NA Compared to the Solution Formulation in Healthy Volunteers

Healthy
Federico II University

Recruiting

Evaluation of Surgical Complications and DFS in Obese Rectal Cancer Patients

Rectal Cancer | Obesity, Morbid | Surgery-Complications

Italy
MolecuLight Inc.

Unknown

A Prospective Evaluation of Clinical Equivalence Between iX and PID

Wound

Canada
Octapharma

Completed

A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push

Primary Immunodeficiency

United Kingdom, Australia, Germany, Italy
Ono Academic College

Completed

Collaborative Consultation for Participation Among Students With IDD

Mental Retardation and Developmental Disabilities With Organic Condition
Boehringer Ingelheim

Completed

Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BS

Healthy
National University Hospital, Singapore

Completed

Intragastric Balloon for Treatment of Non Alcoholic Steatohepatitis (NASH)

Non Alcoholic Steatohepatitis

Singapore
Boehringer Ingelheim

Completed

Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)

Hepatitis C, Chronic

United States, Argentina, Australia, Austria, Canada, Czech Republic, France, Germany, Korea, Republic of, Netherlands, Portugal, Romania, Spain, Switzerland, United Kingdom
Kyungpook National University Chilgok Hospital
Kyungpook National University Hospital

Completed

Impact of the Type of Reconstruction Methods on Diabetes Following Laparoscopic Distal Gastrectomy in Patients With Gastric Cancer and Type 2 Diabetes

Diabetes Mellitus, Type 2 | Stomach Neoplasms

Korea, Republic of
Washington University School of Medicine
American Cancer Society, Inc.

Completed

Improving Cancer Patients' Insurance Choices (I Can PIC)

Cancer | Health Literacy | Health Insurance | Health Services Accessibility | Informed Decision Making

United States
University of Pittsburgh
Merck Sharp & Dohme LLC; RTI International; Rite Aid Corp.; Pharmacy Quality Alliance

Completed

Effect of Community Pharmacist Intervention on Adherence to Long-Term Medications (ECO-PHIL)

Medication Adherence

United States
PATH

Not yet recruiting

Developing a Screening Tool for Primary Immunodeficiency Disease (PID) in Pakistan

Primary Immunodeficiency Diseases

Pakistan
Apollo Endosurgery, Inc.

Completed

A Study of BioEnterics® Intragastric Balloon (BIB®) System to Assist in the Weight Management of Obese Subjects

Obesity

United States
Boehringer Ingelheim

Completed

4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany
University of North Carolina, Chapel Hill
The Hospital for Sick Children; Washington University School of Medicine; McGill... and other collaborators

Recruiting

Defining the Genetic Etiology of Suppurative Lung Disease in Children and Adults

Primary Ciliary Dyskinesia | Kartagener Syndrome | Primary Immune Deficiency

United States, Canada
PT Bio Farma

Completed

Comparison of Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) With Pentabio® Vaccine Primed With Recombinant Hepatitis B

Safety | Immunogenicity

Indonesia
Medical College of Wisconsin

Withdrawn

INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Relapse Multiple Myeloma
Weill Medical College of Cornell University
National Institute of Mental Health (NIMH)

Completed

Problem-Solving Therapy for People With Major Depression and Chronic Obstructive Pulmonary Disease

Depression | Pulmonary Disease, Chronic Obstructive

United States
Universitair Ziekenhuis Brussel
Fund for Scientific Research, Flanders, Belgium; Alexianen Zorggroep Tienen; ... and other collaborators

Recruiting

A Dimensional Model for Personality Disorders in Later Life

Psychiatric Disorders

Belgium, Netherlands
Sansum Diabetes Research Institute
Juvenile Diabetes Research Foundation; University of California, Santa Barbara

Completed

Feasibility Study of PID Versus MPC and HMS

Type 1 Diabetes Mellitus

United States
Sansum Diabetes Research Institute
University of California, Santa Barbara

Completed

MPC Versus PID for Closed Loop Insulin Delivery

Type 1 Diabetes Mellitus

United States
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS Administered to Healthy Male Subjects

Healthy
Bial - Portela C S.A.

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 5-1058

Pulmonary Arterial Hypertension | Cardiovascular Disease+Pulmonary Disease

United Kingdom
Mansoura University

Unknown

Intragastric Balloon, Air Versus Fluid Filled: Randomized Prospective Study

Weight Loss | Morbid Obesity | Tolerance

Egypt
Centre Hospitalier Universitaire de Saint Etienne

Completed

The Influence of Age on Bispectral Index Associated With Propofol-induced Sedation

Anesthesia

France
Boehringer Ingelheim

Completed

Drug-drug Interaction Trial of BI 113608 in Combination With Ketoconazole and Voriconazole in Healthy Male Subjects

Healthy

Germany
Boehringer Ingelheim

Completed

Bioavailability and Pharmacokinetics of BI 10773 Tablet in Healthy Male Volunteers

Healthy
Universitat Internacional de Catalunya
Dentaid SL

Completed

Clinical Effects of Two New Chlorhexidine Digluconate Formulations: 0.12% and 0.03%.

Dental Plaque | Side Effects

Spain
Sir Ganga Ram Hospital

Suspended

Incidence of Intraoperative Awareness in Indian Patient Population

Intraoperative Awareness

India
Boehringer Ingelheim

Completed

Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food

Healthy

Germany
Joel Trinity
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Targeting Oxidative Stress to Prevent Vascular and Skeletal Muscle Dysfunction During Disuse

Aging | Oxidative Stress | Skeletal Muscle | Vascular Endothelium | Antioxidants

United States
Hospital Severo Ochoa
Instituto de Salud Carlos III

Completed

Usefulness and Safeness Of Intra-Gastric Balloon Before Bariatric Surgery In Morbid Obesity

Morbid Obesity

Spain
Hadassah Medical Organization

Completed

Bone Quality and Quantity Following Guided Bone Regeneration Prior to Dental Implant Placement

Resorbed Alveolar Ridge Prior to Dental Implant Insertion

Israel
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Belgium, Canada, China, Germany, India, Ireland, Japan, Switzerland
Boehringer Ingelheim

Completed

BI 10773 add-on to Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Argentina, Austria, Czech Republic, Estonia, Finland, France, Germany, Hungary, Latvia, Norway, Romania, Russian Federation, Slovakia, Spain, Ukraine
Region Skane
Lund University

Recruiting

Aspects of Self-harm - Cognition, Imaging and Treatability

Personality Disorders | Self-Harm, Deliberate | Non-Suicidal Self Injury | Attempt Suicide

Sweden
Summit Therapeutics

Completed

Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection (Ri-CoDIFy 1)

Clostridioides Difficile Infection

United States, Australia, Greece, Canada, Spain, Brazil, Poland, Korea, Republic of, Argentina, Bulgaria, Hungary, New Zealand, Romania, Russian Federation
OHSU Knight Cancer Institute
Novartis; Oregon Health and Science University

Not yet recruiting

177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Recurrent Breast Carcinoma | Metastatic Breast Carcinoma

United States
ANRS, Emerging Infectious Diseases
Janssen Pharmaceuticals

Completed

Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa (MOBIDIP)

HIV Infection

Cameroon, Burkina Faso, Senegal
Bial - Portela C S.A.

Completed

A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067

Parkinson's Disease

Portugal, Romania, Ukraine
Chang Gung Memorial Hospital

Recruiting

To Assess the Impact of theERAS Consensus on Patients With Endoscopic Pituitary Tumor Surgery

Postoperative Complications | Enhanced Recovery After Surgery | Pituitary Tumor

Taiwan
National Cancer Institute (NCI)
Celgene Corporation

Active, not recruiting

Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma

Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma

Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent High Grade B-Cell Lymphoma | Recurrent Aggressive Non-Hodgkin Lymphoma | Recurrent Burkitt Lymphoma | Recurrent Transformed B-Cell Non-Hodgkin Lymphoma

United States

Search clinical trials for: BI 113608 PIB bid

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations